Artiva Biotherapeutics, Inc. Investment Income, Net
Artiva Biotherapeutics, Inc. (ARTV) reported Investment Income, Net of $1.89 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Other Income
us-gaap:InvestmentIncomeNet · last filed 2026-08-06
- Artiva Biotherapeutics, Inc. investment income, net for the quarter ending 2026-06-30 was $1.89M, a 20.82% increase year-over-year.
- Artiva Biotherapeutics, Inc. investment income, net for the quarter ending 2026-03-31 was $912.00K, a 51.07% decline year-over-year.
- Artiva Biotherapeutics, Inc. investment income, net for the quarter ending 2025-12-31 was $1.16M, a 46.62% decline year-over-year.
- Artiva Biotherapeutics, Inc. investment income, net for the quarter ending 2025-09-30 was $1.37M, a 25.68% decline year-over-year.
- Artiva Biotherapeutics, Inc. investment income, net for fiscal 2025 was $5.96M, a 11.40% increase from fiscal 2024.
- Artiva Biotherapeutics, Inc. investment income, net for fiscal 2024 was $5.35M, a 111.01% increase from fiscal 2023.
- Artiva Biotherapeutics, Inc. investment income, net for fiscal 2023 was $2.54M.
| Period end | Investment Income, Net 3 month | Investment Income, Net 6 month | Investment Income, Net 9 month | Investment Income, Net 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.89M 10-Q · filed 2026-08-06 | $2.80M 10-Q · filed 2026-08-06 | $3.96M derived: sum of 3 quarters · filed 2026-08-06 | $5.33M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $912.00K 10-Q · filed 2026-05-08 | $2.07M derived: sum of 2 quarters · filed 2026-05-08 | $3.45M derived: sum of 3 quarters · filed 2026-05-08 | $5.01M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $1.16M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $2.53M derived: sum of 2 quarters · filed 2026-03-10 | $4.09M derived: sum of 3 quarters · filed 2026-08-06 | $5.96M 10-K · filed 2026-03-10 |
| 2025-09-30 | $1.37M 10-Q · filed 2025-11-12 | $2.93M derived: sum of 2 quarters · filed 2026-08-06 | $4.80M 10-Q · filed 2025-11-12 | $6.97M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $1.56M 10-Q · filed 2026-08-06 | $3.42M 10-Q · filed 2026-08-06 | $5.60M derived: sum of 3 quarters · filed 2026-08-06 | $7.45M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $1.86M 10-Q · filed 2026-05-08 | $4.04M derived: sum of 2 quarters · filed 2026-05-08 | $5.89M derived: sum of 3 quarters · filed 2026-05-08 | $6.56M derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | $2.18M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $4.02M derived: sum of 2 quarters · filed 2026-03-10 | $4.70M derived: sum of 3 quarters · filed 2026-03-10 | $5.35M 10-K · filed 2026-03-10 |
| 2024-09-30 | $1.85M 10-Q · filed 2025-11-12 | $2.52M derived: sum of 2 quarters · filed 2025-11-12 | $3.17M 10-Q · filed 2025-11-12 | $3.75M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $676.00K 10-Q · filed 2025-08-06 | $1.33M 10-Q · filed 2025-08-06 | $1.91M derived: sum of 3 quarters · filed 2025-08-06 | $2.33M derived: sum of 4 quarters · filed 2025-08-06 |
| 2024-03-31 | $650.00K 10-Q · filed 2025-05-08 | $1.23M derived: sum of 2 quarters · filed 2025-05-08 | $1.65M derived: sum of 3 quarters · filed 2025-05-08 | $2.16M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $583.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | $1.00M derived: sum of 2 quarters · filed 2025-03-24 | $1.51M derived: sum of 3 quarters · filed 2025-03-24 | $2.54M 10-K · filed 2025-03-24 |
| 2023-09-30 | $418.00K 10-Q · filed 2024-11-12 | $927.00K derived: sum of 2 quarters · filed 2024-11-12 | $1.95M 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $509.00K 10-Q · filed 2024-08-29 | $1.53M 10-Q · filed 2024-08-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |